Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Net: 2022-2024

Historic Receivables - Net for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $75,000.

  • Corvus Pharmaceuticals' Receivables - Net fell 54.29% to $32,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $32,000, marking a year-over-year decrease of 54.29%. This contributed to the annual value of $75,000 for FY2024, which is 188.46% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Receivables - Net of $75,000 as of FY2024, which was up 188.46% from $26,000 recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Receivables - Net registered a high of $588,000 during FY2022, and its lowest value of $26,000 during FY2023.
  • In the last 3 years, Corvus Pharmaceuticals' Receivables - Net had a median value of $75,000 in 2024 and averaged $229,667.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Receivables - Net crashed by 95.58% in 2023 and then surged by 188.46% in 2024.
  • Corvus Pharmaceuticals' Receivables - Net (Yearly) stood at $588,000 in 2022, then slumped by 95.58% to $26,000 in 2023, then skyrocketed by 188.46% to $75,000 in 2024.